AZD1222 US Phase III Trial

The AstraZeneca’s AZD1222 US Phase III Trial demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease…

Ivermectin Against COVID-19?

The US Food and Drug Administration (FDA) recently writes an article about a growing interest in a drug called ivermectin to treat humans with COVID-19….